Global Viral Vector and Plasmid DNA Manufacturing Market
Global Viral Vector and Plasmid DNA Manufacturing Market

Viral Vector and Plasmid DNA Manufacturing Comprehensive Study by Type (Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other}, Plasmid DNA, Non-Viral Vector), Application (Cancer, Genetic Disorder, Infectious Disease, Other), End-User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes, Others) Players and Region - Global Market Outlook to 2024

Viral Vector and Plasmid DNA Manufacturing Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Aug 2019 Edition 240 Pages 199 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
Viral vectors are the tools to deliver genetic material into cells used by the molecular biologists. Viral vectors are used in gene and cell therapy, prophylactic and therapeutic vaccines, cure genetic disorders and to induce an immune response. Plasmid DNA is a small molecule within a cell which is physically separated from chromosomal DNA and can replicate independently. Plasmid DNA has various applications such as transfection, sequencing, screening clones, restriction digestion, cloning and PCR. The number of methods invented for the purification of plasmid DNA from bacteria. It used in the molecular cloning to analyze bacterial clones.

The market study is being classified by Type (Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other}, Plasmid DNA and Non-Viral Vector), by Application (Cancer, Genetic Disorder, Infectious Disease and Other) and major geographies with country level break-up.

Kaneka Eurogentec S.A. (Japan), FinVector Oy (Finland), Brammer Bio (United States), Cell and Gene Therapy Catapult (United Kingdom), FUJIFILM Diosynth Biotechnologies Inc. (United States), Sanofi (France), Spark Therapeutics (United States), Cobra Biologics Ltd (United Kingdom), UniQure (Netherlands) and MassBiologics (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are 4D Molecular Therapeutics (United States), Renova Therapeutics (United States) and Thermo Fisher Scientific, Inc. (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Viral Vector and Plasmid DNA Manufacturing market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Viral Vector and Plasmid DNA Manufacturing market by Type, Application and Region.

On the basis of geography, the market of Viral Vector and Plasmid DNA Manufacturing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Pharmaceutical and Biopharmaceutical Companies will boost the Viral Vector and Plasmid DNA Manufacturing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • High Prevalence of Cancer, Genetic Diseases and Infectious Diseases
  • Growing Awareness about Cancer Worldwide
  • Increasing R&D Activities

Market Trend
  • Technological Advancements in Manufacturing

Restraints
  • Possibility of Mutagenesis
  • Safety and Efficacy Issues

Opportunities
  • Rising Demand for Gene Therapy
  • Various Investment, Collaboration and Partnership Opportunities

Challenges
  • Stringent Regulatory Framework
  • Challenge of Production of Vector on Large Scale


On 9th May 2017, Kaneka Corporation decided to drastically increase its biopharmaceutical production capacity in Kaneka Eurogentec S.A., a wholly owned group company in Europe. This multi-product facility will increase its production capacity by approximately four times and expand the Kaneka Eurogentec Biologics business, also as a result of enhanced sales & marketing efforts.


Key Target Audience
Viral Vector and Plasmid DNA Manufacturers, Raw Material Suppliers/ Buyers, Distributors, Research Organization and Associations, Government Body & Associations and End-user

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other}
  • Plasmid DNA
  • Non-Viral Vector
By Application
  • Cancer
  • Genetic Disorder
  • Infectious Disease
  • Other
By End-User
  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Cancer, Genetic Diseases and Infectious Diseases
      • 3.2.2. Growing Awareness about Cancer Worldwide
      • 3.2.3. Increasing R&D Activities
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Framework
      • 3.3.2. Challenge of Production of Vector on Large Scale
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Manufacturing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Viral Vector and Plasmid DNA Manufacturing, by Type, Application, End-User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Viral Vector and Plasmid DNA Manufacturing (Value)
      • 5.2.1. Global Viral Vector and Plasmid DNA Manufacturing by: Type (Value)
        • 5.2.1.1. Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other}
        • 5.2.1.2. Plasmid DNA
        • 5.2.1.3. Non-Viral Vector
      • 5.2.2. Global Viral Vector and Plasmid DNA Manufacturing by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Genetic Disorder
        • 5.2.2.3. Infectious Disease
        • 5.2.2.4. Other
      • 5.2.3. Global Viral Vector and Plasmid DNA Manufacturing by: End-User (Value)
        • 5.2.3.1. Pharmaceutical and Biopharmaceutical Companies
        • 5.2.3.2. Research Institutes
        • 5.2.3.3. Others
      • 5.2.4. Global Viral Vector and Plasmid DNA Manufacturing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Viral Vector and Plasmid DNA Manufacturing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Kaneka Eurogentec S.A. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. FinVector Oy (Finland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Brammer Bio (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cell and Gene Therapy Catapult (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. FUJIFILM Diosynth Biotechnologies Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Spark Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cobra Biologics Ltd (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. UniQure (Netherlands)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. MassBiologics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Viral Vector and Plasmid DNA Manufacturing Sale, by Type, Application, End-User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Viral Vector and Plasmid DNA Manufacturing (Value)
      • 7.2.1. Global Viral Vector and Plasmid DNA Manufacturing by: Type (Value)
        • 7.2.1.1. Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other}
        • 7.2.1.2. Plasmid DNA
        • 7.2.1.3. Non-Viral Vector
      • 7.2.2. Global Viral Vector and Plasmid DNA Manufacturing by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Genetic Disorder
        • 7.2.2.3. Infectious Disease
        • 7.2.2.4. Other
      • 7.2.3. Global Viral Vector and Plasmid DNA Manufacturing by: End-User (Value)
        • 7.2.3.1. Pharmaceutical and Biopharmaceutical Companies
        • 7.2.3.2. Research Institutes
        • 7.2.3.3. Others
      • 7.2.4. Global Viral Vector and Plasmid DNA Manufacturing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Viral Vector and Plasmid DNA Manufacturing: by Type(USD Million)
  • Table 2. Viral Vector and Plasmid DNA Manufacturing Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other} , by Region USD Million (2013-2018)
  • Table 3. Viral Vector and Plasmid DNA Manufacturing Plasmid DNA , by Region USD Million (2013-2018)
  • Table 4. Viral Vector and Plasmid DNA Manufacturing Non-Viral Vector , by Region USD Million (2013-2018)
  • Table 5. Viral Vector and Plasmid DNA Manufacturing: by Application(USD Million)
  • Table 6. Viral Vector and Plasmid DNA Manufacturing Cancer , by Region USD Million (2013-2018)
  • Table 7. Viral Vector and Plasmid DNA Manufacturing Genetic Disorder , by Region USD Million (2013-2018)
  • Table 8. Viral Vector and Plasmid DNA Manufacturing Infectious Disease , by Region USD Million (2013-2018)
  • Table 9. Viral Vector and Plasmid DNA Manufacturing Other , by Region USD Million (2013-2018)
  • Table 10. Viral Vector and Plasmid DNA Manufacturing: by End-User(USD Million)
  • Table 11. Viral Vector and Plasmid DNA Manufacturing Pharmaceutical and Biopharmaceutical Companies , by Region USD Million (2013-2018)
  • Table 12. Viral Vector and Plasmid DNA Manufacturing Research Institutes , by Region USD Million (2013-2018)
  • Table 13. Viral Vector and Plasmid DNA Manufacturing Others , by Region USD Million (2013-2018)
  • Table 14. South America Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2013-2018)
  • Table 15. South America Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 16. South America Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 17. South America Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 18. Brazil Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 19. Brazil Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 20. Brazil Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 21. Argentina Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 22. Argentina Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 23. Argentina Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 24. Rest of South America Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 25. Rest of South America Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 26. Rest of South America Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 27. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2013-2018)
  • Table 28. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 29. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 30. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 31. China Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 32. China Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 33. China Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 34. Japan Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 35. Japan Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 36. Japan Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 37. India Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 38. India Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 39. India Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 40. South Korea Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 41. South Korea Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 42. South Korea Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 43. Taiwan Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 44. Taiwan Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 45. Taiwan Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 46. Australia Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 47. Australia Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 48. Australia Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 52. Europe Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2013-2018)
  • Table 53. Europe Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 54. Europe Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 55. Europe Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 56. Germany Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 57. Germany Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 58. Germany Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 59. France Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 60. France Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 61. France Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 62. Italy Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 63. Italy Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 64. Italy Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 65. United Kingdom Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 66. United Kingdom Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 67. United Kingdom Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 68. Netherlands Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 69. Netherlands Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 70. Netherlands Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 71. Rest of Europe Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 72. Rest of Europe Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 73. Rest of Europe Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 74. MEA Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2013-2018)
  • Table 75. MEA Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 76. MEA Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 77. MEA Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 78. Middle East Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 79. Middle East Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 80. Middle East Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 81. Africa Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 82. Africa Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 83. Africa Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 84. North America Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2013-2018)
  • Table 85. North America Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 86. North America Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 87. North America Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 88. United States Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 89. United States Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 90. United States Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 91. Canada Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 92. Canada Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 93. Canada Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 94. Mexico Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2013-2018)
  • Table 95. Mexico Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2013-2018)
  • Table 96. Mexico Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2013-2018)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Viral Vector and Plasmid DNA Manufacturing: by Type(USD Million)
  • Table 108. Viral Vector and Plasmid DNA Manufacturing Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other} , by Region USD Million (2019-2024)
  • Table 109. Viral Vector and Plasmid DNA Manufacturing Plasmid DNA , by Region USD Million (2019-2024)
  • Table 110. Viral Vector and Plasmid DNA Manufacturing Non-Viral Vector , by Region USD Million (2019-2024)
  • Table 111. Viral Vector and Plasmid DNA Manufacturing: by Application(USD Million)
  • Table 112. Viral Vector and Plasmid DNA Manufacturing Cancer , by Region USD Million (2019-2024)
  • Table 113. Viral Vector and Plasmid DNA Manufacturing Genetic Disorder , by Region USD Million (2019-2024)
  • Table 114. Viral Vector and Plasmid DNA Manufacturing Infectious Disease , by Region USD Million (2019-2024)
  • Table 115. Viral Vector and Plasmid DNA Manufacturing Other , by Region USD Million (2019-2024)
  • Table 116. Viral Vector and Plasmid DNA Manufacturing: by End-User(USD Million)
  • Table 117. Viral Vector and Plasmid DNA Manufacturing Pharmaceutical and Biopharmaceutical Companies , by Region USD Million (2019-2024)
  • Table 118. Viral Vector and Plasmid DNA Manufacturing Research Institutes , by Region USD Million (2019-2024)
  • Table 119. Viral Vector and Plasmid DNA Manufacturing Others , by Region USD Million (2019-2024)
  • Table 120. South America Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2019-2024)
  • Table 121. South America Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 122. South America Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 123. South America Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 124. Brazil Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 125. Brazil Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 126. Brazil Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 127. Argentina Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 128. Argentina Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 129. Argentina Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 130. Rest of South America Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 131. Rest of South America Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 132. Rest of South America Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 133. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2019-2024)
  • Table 134. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 135. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 136. Asia Pacific Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 137. China Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 138. China Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 139. China Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 140. Japan Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 141. Japan Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 142. Japan Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 143. India Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 144. India Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 145. India Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 146. South Korea Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 147. South Korea Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 148. South Korea Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 149. Taiwan Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 150. Taiwan Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 151. Taiwan Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 152. Australia Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 153. Australia Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 154. Australia Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 155. Rest of Asia-Pacific Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 156. Rest of Asia-Pacific Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 157. Rest of Asia-Pacific Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 158. Europe Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2019-2024)
  • Table 159. Europe Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 160. Europe Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 161. Europe Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 162. Germany Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 163. Germany Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 164. Germany Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 165. France Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 166. France Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 167. France Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 168. Italy Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 169. Italy Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 170. Italy Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 171. United Kingdom Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 172. United Kingdom Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 173. United Kingdom Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 174. Netherlands Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 175. Netherlands Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 176. Netherlands Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 177. Rest of Europe Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 178. Rest of Europe Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 179. Rest of Europe Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 180. MEA Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2019-2024)
  • Table 181. MEA Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 182. MEA Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 183. MEA Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 184. Middle East Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 185. Middle East Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 186. Middle East Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 187. Africa Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 188. Africa Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 189. Africa Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 190. North America Viral Vector and Plasmid DNA Manufacturing, by Country USD Million (2019-2024)
  • Table 191. North America Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 192. North America Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 193. North America Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 194. United States Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 195. United States Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 196. United States Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 197. Canada Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 198. Canada Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 199. Canada Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 200. Mexico Viral Vector and Plasmid DNA Manufacturing, by Type USD Million (2019-2024)
  • Table 201. Mexico Viral Vector and Plasmid DNA Manufacturing, by Application USD Million (2019-2024)
  • Table 202. Mexico Viral Vector and Plasmid DNA Manufacturing, by End-User USD Million (2019-2024)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Viral Vector and Plasmid DNA Manufacturing: by Type USD Million (2013-2018)
  • Figure 5. Global Viral Vector and Plasmid DNA Manufacturing: by Application USD Million (2013-2018)
  • Figure 6. Global Viral Vector and Plasmid DNA Manufacturing: by End-User USD Million (2013-2018)
  • Figure 7. South America Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 8. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 9. Europe Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 10. MEA Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 11. North America Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 12. Global Viral Vector and Plasmid DNA Manufacturing share by Players 2018 (%)
  • Figure 13. Global Viral Vector and Plasmid DNA Manufacturing share by Players (Top 3) 2018(%)
  • Figure 14. Global Viral Vector and Plasmid DNA Manufacturing share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Kaneka Eurogentec S.A. (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Kaneka Eurogentec S.A. (Japan) Revenue: by Geography 2018
  • Figure 18. FinVector Oy (Finland) Revenue, Net Income and Gross profit
  • Figure 19. FinVector Oy (Finland) Revenue: by Geography 2018
  • Figure 20. Brammer Bio (United States) Revenue, Net Income and Gross profit
  • Figure 21. Brammer Bio (United States) Revenue: by Geography 2018
  • Figure 22. Cell and Gene Therapy Catapult (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Cell and Gene Therapy Catapult (United Kingdom) Revenue: by Geography 2018
  • Figure 24. FUJIFILM Diosynth Biotechnologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. FUJIFILM Diosynth Biotechnologies Inc. (United States) Revenue: by Geography 2018
  • Figure 26. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi (France) Revenue: by Geography 2018
  • Figure 28. Spark Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Spark Therapeutics (United States) Revenue: by Geography 2018
  • Figure 30. Cobra Biologics Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Cobra Biologics Ltd (United Kingdom) Revenue: by Geography 2018
  • Figure 32. UniQure (Netherlands) Revenue, Net Income and Gross profit
  • Figure 33. UniQure (Netherlands) Revenue: by Geography 2018
  • Figure 34. MassBiologics (United States) Revenue, Net Income and Gross profit
  • Figure 35. MassBiologics (United States) Revenue: by Geography 2018
  • Figure 36. Global Viral Vector and Plasmid DNA Manufacturing: by Type USD Million (2019-2024)
  • Figure 37. Global Viral Vector and Plasmid DNA Manufacturing: by Application USD Million (2019-2024)
  • Figure 38. Global Viral Vector and Plasmid DNA Manufacturing: by End-User USD Million (2019-2024)
  • Figure 39. South America Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 40. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 41. Europe Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 42. MEA Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
  • Figure 43. North America Viral Vector and Plasmid DNA Manufacturing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Kaneka Eurogentec S.A. (Japan)
  • FinVector Oy (Finland)
  • Brammer Bio (United States)
  • Cell and Gene Therapy Catapult (United Kingdom)
  • FUJIFILM Diosynth Biotechnologies Inc. (United States)
  • Sanofi (France)
  • Spark Therapeutics (United States)
  • Cobra Biologics Ltd (United Kingdom)
  • UniQure (Netherlands)
  • MassBiologics (United States)
Additional players considered in the study are as follows:
4D Molecular Therapeutics (United States) , Renova Therapeutics (United States) , Thermo Fisher Scientific, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation